Cargando…
Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic
INTRODUCTION: Risankizumab has been approved for the treatment of moderate-to-severe plaque psoriasis; however, real-life data are limited. Our objectives were to evaluate the effectiveness and safety of risankizumab and its impact on the quality of life of patients with psoriasis in a real-world se...
Autores principales: | Gkalpakiotis, Spyridon, Cetkovska, Petra, Arenberger, Petr, Dolezal, Tomas, Arenbergerova, Monika, Velackova, Barbora, Fialova, Jorga, Kojanova, Martina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179080/ https://www.ncbi.nlm.nih.gov/pubmed/34089479 http://dx.doi.org/10.1007/s13555-021-00556-2 |
Ejemplares similares
-
Real-World Evidence From More Than 1000 Patients Treated With Adalimumab For Moderate-to-Severe Psoriasis in the Czech Republic
por: Kojanova, Martina, et al.
Publicado: (2021) -
Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry
por: Hugo, Jan, et al.
Publicado: (2023) -
Isolated Melanocytic Hyperpigmentation of the Distal Digits – A Case Report and Review of the Literature
por: Marques, Emanuel C., et al.
Publicado: (2022) -
Unusual Periungual Nodulocystic Lesions Leading to the Diagnosis of Extranodal Marginal Zone Lymphoma
por: Gkalpakiotis, Spyridon, et al.
Publicado: (2020) -
Risankizumab for psoriasis
Publicado: (2020)